KLK3 and posterior cortical atrophy: PHI helps distinguish PCa from benign prostatic conditions and is intended for a more refined population (men aged 50+ with 4.0 to 10.0 ng/mL total PSA, and non-suspicious DRE) than ClarityDX Prostate.